Subramanian and associates report that their randomized controlled trial originally was powered on the basis of an overall sample size of 135 patients (90 in the bevacizumab group and 45 in the ranibizumab group); however, the results presented in their article refer to a total of only 20 patients, which is less than 15% of the population planned at the beginning of the study.

It is therefore surprising to see that, despite the enrollment of a macroscopically insufficient population, the authors draw the conclusion that this controlled study “shows no difference in efficacy between the two treatments.”

On the contrary, these results do not allow one to draw any conclusions about the relative efficacy of the two treatments. Furthermore, this article may induce clinicians to think that bevacizumab and ranibizumab are equally effective, even though this conclusion is far from being demonstrated by these experimental results.